{"product_id":"biolegend-100742","title":"Biolegend, 100742, Brilliant Violet 650™ anti-mouse CD8a Antibody, 50μg","description":"\u003cp\u003eCD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)\/β(CD8b) heterodimer and α\/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α\/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α\/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α\/α homodimer is expressed on a subset of γ\/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.\u003cbr\u003e\n50μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Mouse thymus or spleen\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions.\u003cbr\u003e\nConcentration: µg sizes: 0.2 mg\/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660\/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed Clark JT, et al. 2023. Cell Rep. 42:112147. PubMed Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed Schädlich IS, et al. 2022. iScience. 25:104470. PubMed Kuczynski EA, et al. 2022. EMBO Mol Med. 14:e15816. PubMed Gary EN, et al. 2022. Cell Rep Med. 3:100693. PubMed Klaus T, et al. 2022. JCI Insight. 7: . PubMed Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed Gonçalves R, et al. 2023. iScience. 26:105972. PubMed Sylvester MA, et al. 2022. Am J Physiol Renal Physiol. 322:F245. PubMed Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed Wiesner DL, et al. 2020. Cell Host Microbe. 614:27. PubMed Boyd DF, et al. 2020. Nature. 587:466. PubMed Kloepper J, et al. 2016. Proc Natl Acad Sci U S A. 113: 4476-4481. PubMed Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed Sauter M, et al. 2022. iScience. 25:103677. PubMed Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed Kumar V, et al. 2022. Front Cardiovasc Med. 9:992653. PubMed Su W, et al. 2020. Cell Metabolism. 32(6):996-1011.e7. PubMed Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed Han Y et al. 2019. Cell reports. 27(3):835-846 . PubMed Kumar S, et al. 2021. Cancer Discov. 11:2050. PubMed Linnerbauer M, et al. 2022. Front Immunol. 12:800128. PubMed Marangoni F, et al. 2021. Cell. . PubMed Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed Gary EN, et al. 2021. iScience. 24(7):102699. PubMed MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed Sidwell T, et al. 2020. Nat Commun. 0.633333333. PubMed McAndrews KM, et al. 2021. Oncogene. 40:4440. PubMed Dokoshi T, et al. 2021. J Clin Invest. 131:. PubMed Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed Chen Z et al. 2019. Immunity. 51(5):840-855 . PubMed Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed Roberta Zappasodi et al. 2018. Cancer cell. 33(6):1017-1032 . PubMed , et al. 2021. Eur J Immunol. 51:2708. PubMed Carter TJ, et al. 2021. Small. 17:e2005241. PubMed Walton ZE et al. 2018. Cell. 174(1):72-87 . PubMed Zhou Z, et al. 2022. Infect Immun. 90:e0045321. PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Chiang HY, et al. 2022. Nat Commun. 13:874. PubMed Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed Herrera R, et al. 2015. Infect Immun . 83: 3771 - 3780.. PubMed Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed \u0026amp;Sacute;ledzi\u0026amp;nacute;ska A, et al. 2020. Immunity. 52(1):151-166.e6.. PubMed Yeung F, et al. 2020. Cell Host \u0026amp; Microbe. 27(5):809-822. PubMed Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed Qadir AS, et al. 2021. iScience. 24:103348. PubMed McAndrews KM, et al. 2021. J Biol Chem. 296:100523. PubMed Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed Laban H, et al. 2018. J Cell Biol. 217:1503. PubMed Shi H, et al. 2020. Immunity. 51(6):1012-1027.e7.. PubMed Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed Chen Z, et al. 2021. Cell. 184(5):1262-1280.e22. PubMed Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed Silva DA, et al. 2019. Nature. 565:186. PubMed Sun Y, et al. 2020. J Immunol. 205:2649. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Graham JB, et al. 2017. Curr Protoc Mouse Biol. 7:221. PubMed Shi H et al. 2018. Immunity. 49(5):899-914 . PubMed Alam IS, et al. 2020. Cancer Res. 80:4780. PubMed Kong IY, et al. 2020. Cell Rep. 33:108290. PubMed Goc J, et al. 2021. Cell. 184:5015. PubMed Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed He C, et al. 2021. Immunol Cell Biol. 99:611. PubMed Deets KA, et al. 2021. Elife. 10:. PubMed Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed\u003cbr\u003e\nRRID: AB_11124344 (BioLegend Cat. No. 100741) AB_2563056 (BioLegend Cat. No. 100742)\u003cbr\u003e\nStructure: Ig superfamily, CD8α chain, 34 kD\u003cbr\u003e\nDistribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells\u003cbr\u003e\nFunction: Co-receptor for TCR\u003cbr\u003e\nLigand\/Receptor: MHC class I molecule\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.\u003cbr\u003e\nGene ID: 12525\u003cbr\u003e\nUniProt: View information about CD8alpha on UniProt.org\u003cbr\u003e\nClone: 53-6.7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: T8, Lyt2, Ly-2\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862435352745,"sku":"100742","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-100742","provider":"Iright","version":"1.0","type":"link"}